Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 18, 2019

Study Completion Date

June 18, 2019

Conditions

Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer

Interventions

DRUG

cabozantinib-s-malate

Given PO

RADIATION

fluorine F 18 d-FMAU

Undergo 18F PET/FMAU PET scan

PROCEDURE

positron emission tomography

Undergo 18F PET/FMAU PET scan

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT01812668 - Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter